GlassScriptPhysician profile
Jared M Dowhower
NPI 1649654328
$8,868.39
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,895 · 2022: $2,396 · 2023: $3,405 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,567 · Education: $9.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,566.81 |
| Education | $9.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,723.94 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,492.76 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,167.52 | 2021-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $1,067.99 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $1,017.03 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $548.49 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $349.13 | 2022-2023 | Auvelity |
| Neurocrine Biosciences, INC. | $312.38 | 2021-2022 | |
| Lundbeck LLC | $296.07 | 2021-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $180.40 | 2021-2023 | Austedo |
| Idorsia Pharmaceuticals US INC | $149.03 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $144.88 | 2022-2024 | Trintellix |
| Almatica Pharma LLC | $134.88 | 2023 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $127.96 | 2021-2022 | |
| Indivior INC. | $52.51 | 2023 | Perseris |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $48.08 | 2021 | |
| Corium, LLC | $20.00 | 2024 | Azstarys |
| Neuronetics, INC. | $19.72 | 2023 | Neurostar Tms Therapy System |
| Braeburn INC. | $15.62 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Dowhower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.